Literature DB >> 11056309

Modulation of oestrogen action by receptor gene inhibition.

T A Madden1, D Barrow, R A McClelland, J M Gee, R I Nicholson.   

Abstract

Selective oestrogen receptor downregulators (SERDs) are a class of highly effective steroidal antitumour agents that reduce cellular levels of the oestrogen receptor (ER). In this study, we compared the efficacy by which three novel molecular approaches: (1) antisense oligonucleotides; (2) antisense RNA; and (3) dominant negative mutants are able to act as SERDs. Using transient and, where appropriate, stable gene transfection experiments we found that constitutive overexpression of ER antisense RNA and a hormone-binding domain compromised dominant-negative ER mutant (DNER-1), were most effective at downregulating ER expression and/or activity in vitro.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11056309     DOI: 10.1016/s0959-8049(00)00216-1

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  2 in total

1.  Designer monotransregulators provide a basis for a transcriptional therapy for de novo endocrine-resistant breast cancer.

Authors:  Stephanie L Nott; Yanfang Huang; Aja Kalkanoglu; Kathryn Harper; Ming Chen; Scott F Paoni; Bruce M Fenton; Mesut Muyan
Journal:  Mol Med       Date:  2009-11-17       Impact factor: 6.354

2.  DNER modulates the length, polarity and synaptogenesis of spiral ganglion neurons via the Notch signaling pathway.

Authors:  Jintao Du; Xianren Wang; Xiaobo Zhang; Xuemei Zhang; Hongyan Jiang
Journal:  Mol Med Rep       Date:  2017-11-20       Impact factor: 2.952

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.